Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo.

Pharmacogenetics - 1 Dec 1998

Rothen J P, Haefeli W E, Meyer U A, Todesco L, Wenk M

Abstract excerpt

Slow acetylators of the polymorphic N-acetyltransferase 2 (NAT2, EC 2.3.1.5) suffer more often from side-effects of NAT-substrates than fast acetylators. Since concomitant administration of drugs may inhibit NAT2, we studied the influence of acetaminophen on NAT2 in human hepatic cytosol in vitro and in healthy individuals. In-vitro acetylation was assessed in liver homogenate of one fast and one slow acetylator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Arylamine N-Acetyltransferase
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to NAT2 gene

Share to Genotype

Share to Phenotype

Source

Identifiers

PMID: 9918139
DOI: 10.1097/00008571-199812000-00012

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo.PMID 9918139Read ↗

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.Semantic proximity Read ↗

N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation.Semantic proximity Read ↗

Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases.Semantic proximity Read ↗

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Semantic proximity Read ↗

Acetylator status, drug metabolism and disease.Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.Semantic proximity Read ↗

N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.Semantic proximity Read ↗

Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.Semantic proximity Read ↗

Polymorphisms of N-acetyltransferase genes.Semantic proximity Read ↗

Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N-Acetyltransferase NAT2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.